by EpicentRx | Feb 9, 2023 | Conferences
January 2023, San Francisco, California Oral Presentation: Exploring the Clinical Stage TGF-β Fusion Protein Expressing Oncolytic Virus, AdAPT-001 Highlighting the safety and tolerability of TGF-β targeting OV, AdAPT-001 Using correlative studies for measuring...
by EpicentRx | Feb 9, 2023 | Conferences
January 2023, San Francisco, California Poster: Phase 2 randomized, active-controlled, multicenter trial to assess the safety and efficacy of RRx-001 + irinotecan vs. regorafenib + irinotecan in third/fourth-line colorectal cancer.
by EpicentRx | Feb 9, 2023 | Conferences
December 2022, San Antonio, Texas Poster: Treatment of 4T1 Breast Cancer with Liposome-Encapsulated AdAPT-001, a TGF-beta Trap Encoded Oncolytic Adenovirus Currently in a Phase 1/2 Anticancer Trial
by EpicentRx | Feb 9, 2023 | Conferences
November 2022, Boston, Massachusetts Oral Presentation: RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases Evaluate strategy and execution of drug design and translational development Understanding relevant pathology...
by EpicentRx | Feb 9, 2023 | Conferences
November 2022, San Diego, California Oral Presentation: The NLRP3 inhibitor RRx-001 crosses the blood brain barrier and alleviates neuroinflammation in experimental models of Parkinson’s disease
